Back

Effect of low-dose rivaroxaban with low-dose aspirin vs low-dose aspirin on platelet and oxidative biomarkers: a randomized study in diabetes patients with stable peripheral or coronary artery disease

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Challenges and advances in antithrombotic therapy Antiplatelet Drugs ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Bianca Rocca

LUM University, Casamassima (Italy)

6 More presentations in this session

Presentation thumbnail
A randomized, cross-over study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of milvexian with single and dual antiplatelet therapy in healthy participants
Doctor G. Abelian (US)
Abstract Slides
Presentation thumbnail
Antithrombotic strategies in antiphospholipid syndrome with arterial thrombosis: a systematic review and network meta-analysis
Doctor T. Attachaipanich (Chiang Mai, TH)
Abstract Slides
Presentation thumbnail
Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study
Doctor K. Matli (Paris, FR)
Abstract Slides
Presentation thumbnail
CS014 is a novel HDAC inhibitor regulating the platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding
Associate Professor M. Holinstat (Ann Arbor, US)
Abstract Slides
Presentation thumbnail
Aspirin therapy on prophylactic anticoagulation for hospitalized patients with COVID-19: A propensity score-matched cohort analysis of the HOPE-COVID-19 registry.
Doctor F. Santoro (Foggia, IT)
Abstract Slides

Access the full session

Session thumbnail
Challenges and advances in antithrombotic therapy

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Session
State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources